Keytruda, Opdivo Set To Challenge Tecentriq In Bladder Cancer
Phase III trial of Merck's Keytruda stops early with survival benefit as FDA accepts filing of Bristol's Opdivo, which has breakthrough therapy status and priority review.
You may also be interested in...
Keeping track of US FDA approvals last week included watching the creative and the familiar.
Merck claims first Phase III survival data in bladder cancer for Keytruda, while Bristol shows potential for immunotherapy combinations in bladder and head and neck cancers at the annual SITC meeting.
The latest drug development news and highlights from our FDA Performance Tracker.